Martin Schiestl | Chief Science Officer
Sandoz Novartis

Martin Schiestl, Chief Science Officer, Sandoz Novartis

Martin Schiestl obtained his PhD in chemistry with focus on analytical sciences at the University of Innsbruck/Austria in 1996. In the same year he started his work on Biosimilar medicines at Sandoz. He build up the analytical and pharmaceutical development departments for Sandoz' biopharmaceuticals in charge of the biosimilar pipeline and other biotech products of Sandoz. He moved from quality development into the regulatory and policy field in 2009 and since 2015 he is working as Chief Science Officer for Sandoz Biopharmaceuticals.


Biosimilars Day 1 - Tuesday 29th October 2018 @ 09:20

The totality of evidence for the approval of biosimilar etanercept and rituximab

  • The concept of totality of evidence applied
  • Case studies for the development and assessment of biosimilar etanercept and rituximab
  • Tailoring biosimilar development in the future
last published: 17/Jul/18 15:35 GMT
last published: 17/Jul/18 15:35 GMT

back to speakers

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates